MPLT - CIK 0001770069
The table below shows MapLight Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $53.68M | $27.09M | - | $19.79M | $16.81M | - |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $10.82M |
| $4.40M |
| - |
| $3.76M |
| $4.08M |
| - |
| Operating income | -$64.50M | -$31.50M | - | -$23.54M | -$20.89M | - |
| Income tax | - | - | - | - | - | - |
| Net income | -$60.67M | -$29.42M | -$29.85M | -$22.34M | -$19.02M | -$18.40M |
| EPS (diluted) | -$1.34 | -$37.18 | - | -$29.33 | -$25.08 | - |